1998. absence of detectable neutralization, and vice versa, were observed. These results reveal incomplete overlap in the specificities of antibodies that mediate these antiviral activities and provide insights into the relationship between ADCC and neutralization important for the development of antibody-based vaccines and therapies for combating HIV-1 infection. IMPORTANCE This study provides fundamental insights into… Continue reading 1998
Category: Opioid, ??-
Misoprostol and other cAMP-elevating agents are known to inhibit human neutrophil ROS production (19, 42)
Misoprostol and other cAMP-elevating agents are known to inhibit human neutrophil ROS production (19, 42). used in horses to treat NSAID-induced gastrointestinal injury; however, its effects on equine neutrophils have not been identified. We hypothesized that treatment of equine neutrophils with misoprostol would inhibit equine neutrophil adhesion, migration, and ROS production, fluorescence-based adhesion and chemotaxis… Continue reading Misoprostol and other cAMP-elevating agents are known to inhibit human neutrophil ROS production (19, 42)
Keys to success in standardizing pneumococcal assays included: (1) involvement of manufacturers and regulators from the outset; (2) willingness of laboratories to adjust their protocols; (3) availability of a central source of relevant reagents, such as reference sera, antigen sources, bacterial strains; and (4) established WHO reference laboratories as part of WHOs Collaborating Center systems
Keys to success in standardizing pneumococcal assays included: (1) involvement of manufacturers and regulators from the outset; (2) willingness of laboratories to adjust their protocols; (3) availability of a central source of relevant reagents, such as reference sera, antigen sources, bacterial strains; and (4) established WHO reference laboratories as part of WHOs Collaborating Center systems.… Continue reading Keys to success in standardizing pneumococcal assays included: (1) involvement of manufacturers and regulators from the outset; (2) willingness of laboratories to adjust their protocols; (3) availability of a central source of relevant reagents, such as reference sera, antigen sources, bacterial strains; and (4) established WHO reference laboratories as part of WHOs Collaborating Center systems